Effect Analysis of Ozurdex and Anti-VEGF Drugs On Diabetic Macular Edema
Objective To compare the efficacy of Ozurdex and anti-VEGF drugs on Diabetic Macular Edema(DME).Methods Retrospective analysis was used.A total of 28 eyes of 23 DME patients who underwent intravitreal drug injection in the ophthalmology department of the First Affiliated Hospital of Anhui University of Science and Technology(Huainan First People's Hospital)from January 2020 to March 2023 were collected.The patients were divided into three groups according to the treatment plan chosen by the patients and the rule of injection:anti-VEGF1 group:the patients re-ceived intravitreal injection of anti-VEGF drugs(leizμmab,Compaximab,arbocept)of 0.05ml,regular injection three times a month,the total treatment time was 12 weeks,a total of 7 cases(9 eyes);Anti-VEGF2 group:8 patients(10 eyes)re-ceived intravitreal injection of anti-VEGF drug(0.05 ml)for 3 consecutive times with irregular injection interval of 4~6 weeks.The total treatment time was 12~14 weeks.IDI group:8 patients(9 eyes)received a single intravitreal injection of Ozurdex(0.7 mg).SD-OCT was used to monitor the changes of CMT in the three groups within 16 weeks.Results CMT in IDI group and anti-VEGF1 group decreased significantly and to the same extent in 12 weeks,and the mean value was less than 300 μm.In the anti-VEGF2 group,CMT fluctuated in 12~14 weeks,and the mean value was higher than 300 μm.In IDI group,CMT continued to decrease within 8 weeks after treatment,reached the lowest value at 8 weeks,and increased slightly at 12 weeks.In the anti-VEGF1 group,CMT continued to decline within 12 weeks after treatment,and after 16 weeks of treatment,CMT in all three groups recovered to a higher level(above 300 μm),and all needed to be treated again.Conclusions Ozurdex and anti-VEGF drugs can significantly improve the anatomical morphology of macular fovea in DME patients,and Ozurdex can stably maintain the relatively normal anatomical morphology of macular within 12 weeks,while the efficacy of anti-VEGF drugs depends on the compliance of patients,and patients who return to the clinic on time can maintain relatively good anatomical morphology of macular within 12 weeks.